OncoMatch/Brain Cancer — Glioblastoma (GBM)/IDH1
Brain Cancer — Glioblastoma (GBM)IDH1 Clinical Trials
IDH1 mutations occur in approximately 5–10% of primary glioblastoma (typically secondary GBM arising from lower-grade glioma) and define a molecularly distinct, better-prognosis subgroup. Vorasidenib, a brain-penetrant dual IDH1/2 inhibitor, received FDA approval for grade 2 IDH-mutant glioma and is under study in IDH-mutant GBM. Trials investigate vorasidenib, ivosidenib, and IDH inhibitor combinations with alkylating chemotherapy and radiation in IDH-mutant glioblastoma.
Top recruiting IDH1 Brain Cancer — Glioblastoma (GBM) trials
Ranked by phase and US site count.
See all trials matched to your profile →SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Nuvation Bio Inc.
A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery
Hospices Civils de Lyon
A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).
University Hospital Heidelberg
Vorasidenib Maintenance for IDH Mutant Astrocytoma
European Organisation for Research and Treatment of Cancer - EORTC
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Neonc Technologies, Inc.
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Patrick Wen, MD
More IDH1 Brain Cancer — Glioblastoma (GBM) trials
5 international trials (no US sites)
Browse other molecular targets with active Brain Cancer — Glioblastoma (GBM) trials.